Last reviewed · How we verify
HLX53
At a glance
| Generic name | HLX53 |
|---|---|
| Sponsor | Shanghai Henlius Biotech |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. (PHASE2)
- A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HLX53 CI brief — competitive landscape report
- HLX53 updates RSS · CI watch RSS
- Shanghai Henlius Biotech portfolio CI